+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil



Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil



Drug Design, Development and Therapy 12: 41-45



To investigate the predictors of hypophosphatemic osteomalacia induced by adefovir dipivoxil (ADV) and to monitor for early detection. Hospitalized patients who were diagnosed with ADV-related hypo-phosphatemic osteomalacia were recruited and retrospectively analyzed in our hospital from January 2012 to December 2016. A telephone interview was conducted at 1, 3, 6, 9, 12, and 24 months after cessation of ADV. In the 8 patients enrolled in the study, the hypophosphatemic osteomalacia symptoms developed at an average of 5.14 (4-7) years since ADV treatment (10 mg/d). The average alkaline phosphatase (ALP) level was 279.50 (137-548) U/L, which was significantly higher than the normal level (45-125 U/L). The serum phosphorus level was an average of 0.59 (0.43-0.69) mmol/L, which was lower than the normal range (2.06-2.60 mmol/L). Serum calcium levels of the enrolled patients remained within normal limits. Reduced estimated glomerular filtration rate (eGFR <29 mL/min/1.73 m2) was seen in 4 cases. The clinical manifestations were mainly progressive systemic bone and joint pain, frequent fractures, trouble in walking, height reduction (4-6 cm), and so on. After cessation of ADV, symptoms like bone pain resolved gradually. Serum phosphorus level restored to normal in 4.5 months after the withdrawal of ADV. However, in 4 patients, renal function failed to return to normal in 24 months. More attention should be paid to the duration of ADV treatment. The level of serum phosphorus and ALP, as well as renal function, should be monitored for early detection of potential adverse drug reactions.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054701179

Download citation: RISBibTeXText

PMID: 29343941

DOI: 10.2147/DDDT.S140988


Related references

Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors. Bone 93: 97-103, 2016

Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?. Drug Design, Development and Therapy 13: 1127-1133, 2019

Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B. Journal of Clinical Endocrinology and Metabolism 95(2): 479-480, 2010

Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. Journal of Clinical Pharmacy and Therapeutics 38(4): 321-326, 2014

Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. Journal of Clinical Pharmacy and Therapeutics 40(3): 345-348, 2016

Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil. Clinical and Experimental Nephrology 17(1): 147-148, 2013

Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. Internal Medicine 53(3): 233-237, 2014

Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao 31(11): 1956, 2013

Two Cases of Hypophosphatemic Osteomalacia After Long-term Low Dose Adefovir Therapy in Chronic Hepatitis B and Literature Review. Journal of Bone Metabolism 21(1): 76-83, 2014

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. Bmc Pharmacology and Toxicology 19(1): 23, 2018

Fanconi's Syndrome and Hypophosphatemic Osteomalacia Associated with Adefovir Dipivoxil: A Case Report. Nihon Naika Gakkai Zasshi 103(6): 1388-1390, 2014

Low-dose adefovir-induced hypophosphatemic osteomalacia on whole-body bone scintigraphy. Nuclear Medicine and Molecular Imaging 47(4): 294-296, 2014

Low-dose adefovir dipivoxil may induce Fanconi syndrome: clinical characteristics and long-term follow-up for Chinese patients. Antiviral Therapy 20(6): 603-611, 2016

Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. Journal of Bone and Mineral Metabolism 31(2): 240-246, 2013

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. Journal of Medical Case Reports 13(1): 99, 2019